Iovance Biotherapeutics, Inc.
IOVA
Kedudukan dalam Saham
#2785
Iovance Biotherapeutics, Inc., a biotechnology firm currently in the clinical... Iovance Biotherapeutics, Inc., a biotechnology firm currently in the clinical development stage, is committed to discovering and bringing to market cancer immunotherapy solutions. Its core mission involves leveraging the patient's own immune system to effectively combat and eradicate cancerous cells. The company is presently conducting six Phase 2 clinical trials. These include study C-144-01, evaluating its primary experimental compound, lifileucel, for individuals with advanced melanoma. Another trial, C-145-04, is assessing lifileucel's potential for treating cervical cancer that is recurrent, metastatic, or persistent. Additionally, investigational product LN-145 is undergoing evaluation in trial C-145-03 for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. maintains strategic alliances and licensing arrangements with several distinguished entities, including H. Lee Moffitt Cancer Center, M.D. Anderson Cancer Center, Ohio State University, the Centre hospitalier de l'Université de Montreal, Cellectis S.A., and Novartis Pharma AG. Established in 2007, the company was previously known as Lion Biotechnologies, Inc. It adopted its current name, Iovance Biotherapeutics, Inc., in June 2017. Its corporate offices are located in San Carlos, California.
Harga Saham
$14.87
Modal Pasaran
$6.74B
Perubahan (1 hari)
4.64%
Perubahan (1 tahun)
540.91%
Negara
US
Perdagangan Iovance Biotherapeutics, Inc. (IOVA)
Kategori
Healthcare
Nisbah P/S bagi Iovance Biotherapeutics, Inc. (IOVA)
Nisbah P/S pada October 2026 TTM: 19.81
Menurut laporan kewangan dan harga saham terkini Iovance Biotherapeutics, Inc., nisbah P/S semasa (TTM) ialah 19.81. Pada akhir 2023, nisbah P/S syarikat ialah 1.61K.
Sejarah nisbah P/S untuk Iovance Biotherapeutics, Inc. dari 2008 hingga 2026
Nisbah P/S pada akhir setiap tahun
| Tahun | Nisbah P/S | Ubah |
|---|---|---|
| 2026 (TTM) | 19.81 | 51.55% |
| 2024 | 13.07 | -99.19% |
| 2023 | 1.61K | 0.00% |
| 2022 | 0.00 | 0.00% |
| 2021 | 0.00 | 0.00% |
| 2020 | 0.00 | 0.00% |
| 2019 | 0.00 | 0.00% |
| 2018 | 0.00 | 0.00% |
| 2017 | 0.00 | 0.00% |
| 2016 | 0.00 | 0.00% |
| 2015 | 0.00 | 0.00% |
| 2014 | 0.00 | 0.00% |
| 2013 | 0.00 | 0.00% |
| 2012 | 0.00 | 0.00% |
| 2011 | 0.00 | 0.00% |
| 2010 | 0.00 | 0.00% |
| 2009 | 0.00 | 0.00% |
| 2008 | 0.00 | 0.00% |
Nisbah P/S untuk syarikat atau pesaing yang serupa
| Syarikat | Nisbah P/S | Perbezaan Nisbah P/S | Negara |
|---|---|---|---|
| 10.02 | -49.40% |
US
|
|
| 40.55 | 104.73% |
US
|
|
| 3.96 | -80.00% |
AU
|
|
| - | - |
CH
|
|
| 10.15 | -48.77% |
NL
|
